Review Article

Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy

Ang Gao1,2, Xian-li Hu2, Madiha Saeed2, Bin-fan Chen2, Ya-ping Li2,4, Hai-jun Yu2,4
1 School of Pharmaceutical Science, Jiangsu University, Zhenjiang 212013, China
2 School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China
2 State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
4 University of Chinese Academy of Sciences, Beijing 100049, China
Correspondence to: Hai-jun Yu: hjyu@simm.ac.cn,
DOI: 10.1038/s41401-019-0281-1
Received: 13 May 2019
Accepted: 23 June 2019
Advance online: 1 August 2019

Abstract

The clinical performance of conventional cancer therapy approaches (surgery, radiotherapy, and chemotherapy) has been challenged by tumor metastasis and recurrence that is mainly responsible for cancer-caused mortalities. The cancer immunotherapy is being emerged nowadays as a promising therapeutic modality in order to achieve a highly efficient therapeutic performance while circumventing tumor metastasis and relapse. Liposomal nanoparticles (NPs) may serve as an ideal platform for systemic delivery of the immune modulators. In this review, we summarize the cutting-edge progresses in liposomal NPs for cancer immunotherapy, with focus on dendritic cells, T cells, tumor cells, natural killer cells, and macrophages. The review highlights the major challenges and provides a perspective regarding the clinical translation of liposomal nanoparticle-based immunotherapy.
Keywords: immunotherapy; liposomal NPs; dendritic cells; T cells; tumor cells; natural killer cells; macrophages; nanomedicine

Article Options

Download Citation

Cited times in Scopus

Share